Scott Leftwich - 21 Aug 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Reporting relationship: Director
Issuer ticker: CLDI
Reported as of: 21 Aug 2025
Net transaction value: +$250,000
SEC form: 4
Accepted by SEC: 25 Aug 2025, 20:47:37 UTC
Prior SEC filing: 15 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Jackson, Attorney-in-fact

Key filing fact

Scott Leftwich filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 25 Aug 2025.

Key facts

This page summarizes Scott Leftwich's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Aug 2025, 20:47.

Change

Previous filing in this sequence was filed on 15 Jul 2025.
Current net transaction value: +$250,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001991668 Primary reporting owner

Leftwich Scott

Relationship: Director
Address: C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
Signature: /s/ Andrew Jackson, Attorney-in-fact
Signature date: 25 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLDI transaction

Common Stock

Purchase

Transaction value: $250,000
Shares: +125,000
Change %: +2212%
Price: $2.00^*
Shares after: 130,650
Date: 21 Aug 2025
Ownership: Direct
Footnotes: F1, F2

CLDI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 14,672
Date: 21 Aug 2025
Ownership: By SECBL, LLC
Footnotes: F3

CLDI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,309
Date: 21 Aug 2025
Ownership: By WEBCL, LLC
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLDI transaction Derivative

Warrant (right to buy)

Purchase

Transaction value
Shares: +125,000
Change %
Price
Shares after: 125,000
Date: 21 Aug 2025
Ownership: Direct
Underlying class: Common stock
Underlying amount: 125,000
Exercise price: $2.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025.

Footnote F2

Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.

Footnote F3

The reporting person is the managing member of SECBL, LLC and WEBCL, LLC, as such the reporting person may be deemed to have beneficial ownership of the common stock held by SECBL, LLC and WEBCL, LLC.

SEC remarks

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated July 2, 2024.)